full issue - Association of Biotechnology and Pharmacy

More documents

Recommendations

Info

Current Trends in Biotechnology and PharmacyVol. 5 (2) 1110-1122 April 2011. ISSN 0973-8916 (Print), 2230-7303 (Online)1115Table 1. Composition of Carvedilol loaded nano emulsions.Volume of oil phase (ml) Quantity of Volume ofCode surfactant (mg) aqueous phase (ml)Sesame oil Olive oil Brij 97 Tween 80C1 100 - 150 - 10C2 150 - 150 - 10C3 200 - 150 - 10C4 150 - 125 - 10C5 150 - 175 - 10C6 100 - - 150 10C7 150 - 150 10C8 200 - - 150 10C9 150 - - 125 10C10 150 - - 175 10C11 - 100 150 - 10C12 - 150 150 - 10C13 - 200 150 - 10C14 - 150 125 - 10C15 - 150 175 - 10C16 - 100 - 150 10C17 - 150 - 150 10C18 - 200 - 150 10C19 - 150 - 125 10C20 - 150 - 175 10zeta size (nm)volume of oil phaseFig.1. Effect of oil phase volume on particle size ofnano emulsions a C, S, O, B and T represents thecarvedilol, Sesame oil, Olive oil, Brij 97 and Tween 80respectively.1% tween 80 for the formulations (C14, C4, C7and C17) that showed maximum drug loading andnarrow globule size and narrow PDI . The invitrodrug release profiles for the formulationsC14, C4, C7 and C17 were shown in Fig-2A and2B. The cumulative amount released was63.68±0.8%, 31.8±3.0%, 27.56±9.2%, and38.04±5.9% in formulations C14, C4, C7 and C17respectively. Plots of log % drug remaining againsttime were linear which indicates that the rate ofdrug release follows first order kinetics.X-ray diffraction studies: X-ray diffractionstudies were carried out to reveal the crystallinemodification of the drug during preparation of nanoKoteswari Poluri et al
Current Trends in Biotechnology and PharmacyVol. 5 (2) 1110-1122 April 2011. ISSN 0973-8916 (Print), 2230-7303 (Online)1116Table 2. Particle size, zeta potential, polydispersity index and % drug contentmeasurements of optimized carvedilol nano emulsions.Code Particle size Polydispersity Zeta potential %drug content(nm)(mv)C1 33.4±3.9 0.248±0.05 -7.45±0.56 50.07±0.8C2 75.74±0.92 0.07±0.08 -6.6±0.54 89.27±0.72C3 169.63±1.4 0.285±0.04 -6.8±0.27 91.22±0.46C4 97.77±0.9 0.116±0.07 -6.45±0.46 91.92±0.9C5 67.75±1.58 0.37±0.02 -6.67±0.68 85.89±1.32C6 63.09±1.19 0.176±0.02 -2.87±0.65 30.19±0.43C7 66.58±1.54 0.188±0.06 -4.09±0.78 87.63±1.14C8 175.29±6.9 0.31±0.029 -7.04±0.29 87.94±0.68C9 69.45±9.42 0.28±0.063 -6.04±0.42 89.16±0.74C10 75.54±1.07 0.051±0.04 -9.04±0.16 87.72±1.7C11 34.45±1.167 0.31±0.01 -4.53±0.3 51.1±1.56C12 45.49±0.73 0.326±0.04 -6.84±0.41 77.91±1.58C13 153.76±2.72 0.33±0.02 -10.37±1.69 88.69±2.04C14 54.18±0.37 0.12±0.04 -14.18±0.72 98.93±1.31C15 38.81±1.32 0.36±0.03 -13.26±0.34 98.20±0.6C16 47.38±1.61 0.26±0.02 -6.35±0.6 43.81±2.68C17 75.21±1.8 0.38±0.06 -5.7±0.36 89.47±1.15C18 183.56±1.78 0.35±0.026 -7.78±0.44 89.94±1.38C19 61.47±4.21 0.31±0.025 -4.49±1.62 87.25±1.69C20 60.73±0.54 0.251±0.04 -5.69±1.62 88.47±0.57Data represents mean ± standard deviation (n=3)cumulative % drug released2 (a)C4C7C14C170 5 10 15 20 25 30 0 5 10 15 20 25 30Time in HrTime in HrFig. 2A and 2B. In-vitro drug release profileslog % drug remaining2 (b)C4C7C14C17Formulation, characterization and Pharmacokinetic studies
Page 3 and 4: ISSN 0973-8916Current Trends inBiot
Page 6 and 7: Current Trends in Biotechnology and
Page 37: Current Trends in Biotechnology and
Page 55: Current Trends in Biotechnology and
Page 88 and 89:
Current Trends in Biotechnology and
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 133:
(December 7-9, 2011)Venue: Karunya
show all

full issue - Association of Biotechnology and Pharmacy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?